- Home
- CATX vs MDXG Comparison
CATX vs MDXG Comparison
Compare CATX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | MDXG |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.9M | 530.2M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CATX | MDXG |
|---|---|---|
| Price | $3.43 | $3.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $12.11 | $9.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $1.96 | $3.03 |
| 52 Week High | $6.16 | $7.99 |
Technical Indicators
Market Signals| Indicator | CATX | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 54.84 |
| Support Level | $2.85 | $3.77 |
| Resistance Level | $4.27 | $3.84 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 66.06 | 53.19 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.